

Nerlynx

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	C.I HUMAN AND VETERINARY MEDICINAL	22/05/2025		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.



² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/VR/0000265110	PRODUCTS - C.I.z Other variation - Accepted		
	C.I.z – To update sections 1, 2, 3 and 4 of		
	the PL to ensure alignment of the		
	information with the approved sections of		
	the SmPC, as well as to add some key		
	information to improve understanding by the		
	patients. In addition, some linguistic		
	improvements have been included in the		
	French translation of the PI and the date of		
	latest renewal has been included in section 9		
	of the SmPC.		